Innere Medizin (Heidelberg, Germany)最新文献_第2页

[Purple urine bag syndrome]. [紫尿袋综合征]。

Innere Medizin (Heidelberg, Germany) Pub Date : 2025-07-01 Epub Date: 2025-03-12 DOI: 10.1007/s00108-025-01882-9

Marco Franzoi, Florian Strasser, Hans Peter Gröchenig

引用次数: 0

[Fibrotic diseases]. (纤维化疾病)。

Innere Medizin (Heidelberg, Germany) Pub Date : 2025-07-01 Epub Date: 2025-07-04 DOI: 10.1007/s00108-025-01928-y

Ulf Müller-Ladner, Claus F Vogelmeier

引用次数: 0

Steuerung. 管理.

Innere Medizin (Heidelberg, Germany) Pub Date : 2025-07-01 DOI: 10.1007/s00108-025-01940-2

引用次数: 0

[Postbronchoscopy psychosis associated with metabolic alkalosis]. [与代谢性碱中毒有关的支气管镜术后精神病]。

Innere Medizin (Heidelberg, Germany) Pub Date : 2025-07-01 Epub Date: 2025-04-04 DOI: 10.1007/s00108-025-01881-w

Stephan Schroll, Louisa Dietmaier, Christiane Girlich, Michael Pfeifer

引用次数: 0

[Donor lymphocyte infusion after allogeneic stem cell transplantation]. [同种异体干细胞移植后供体淋巴细胞输注]。

Innere Medizin (Heidelberg, Germany) Pub Date : 2025-07-01 DOI: 10.1007/s00108-025-01948-8

Christoph Schmid, Hans-Jochem Kolb

{"title":"[Donor lymphocyte infusion after allogeneic stem cell transplantation].","authors":"Christoph Schmid, Hans-Jochem Kolb","doi":"10.1007/s00108-025-01948-8","DOIUrl":"https://doi.org/10.1007/s00108-025-01948-8","url":null,"abstract":"The transfusion of donor lymphocytes after allogeneic stem cell transplantation (known as donor lymphocyte infusion, DLI) is the oldest form of cellular immunotherapy. The therapeutic effect is based on the polyclonal reaction of the transferred immune effector cells of the donor against the underlying malignant disease, the graft versus malignancy reaction (GvM). Based on findings from the canine model, DLI has been used for over 30 years, primarily for the prophylaxis and treatment of recurrence of hematological neoplasms after allogeneic transplantation, whereby the various diseases exhibit very different sensitivities to the GvM effect. As a result, both the indications and the potential combination of DLI with classical chemotherapy and newer drugs are different. The main complication of DLI is the induction of a graft versus host disease, the risk of which is influenced in particular by the human leukocyte antigen (HLA) match between donor and recipient as well as the dosage and timing of DLI. Based on large registry data, recommendations for the implementation of DLI in the various constellations and indications have been developed in recent years, which have already proven to be easy to implement in practice. This article summarizes the basic principles, clinical use and recommendations for application.","PeriodicalId":73385,"journal":{"name":"Innere Medizin (Heidelberg, Germany)","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144546459","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

[Fibrotic diseases in the gastrointestinal tract : Liver fibrosis and more]. [胃肠道纤维化疾病：肝纤维化等]。

Innere Medizin (Heidelberg, Germany) Pub Date : 2025-07-01 Epub Date: 2025-03-03 DOI: 10.1007/s00108-025-01869-6

Elke Roeb

{"title":"[Fibrotic diseases in the gastrointestinal tract : Liver fibrosis and more].","authors":"Elke Roeb","doi":"10.1007/s00108-025-01869-6","DOIUrl":"10.1007/s00108-025-01869-6","url":null,"abstract":"Chronic liver damage, such as metabolic dysfunction-associated steatotic liver disease (MASLD), viral hepatitis B or C, cholestatic hepatitis (PBC, PSC), toxic damage (alcohol) or genetic alterations (hemochromatosis, Wilson's disease, etc.) usually cause a chronic inflammatory response in liver cells or bile duct epithelial cells. In the long term this chronic inflammatory response can lead to scarring of the liver, a condition known as fibrosis. The development of liver fibrosis is largely independent of the causative agent, although the pattern of initial fibrosis (periportal, pericentral or sinusoidal) can vary. Untreated and progressive fibrosis can sometimes lead to complete architectural deconstruction and deposition of connective tissue in the liver, intestines and other parenchymal organs, with a gradual loss of function. In the end stage of liver cirrhosis, portal hypertension, encephalopathy, bleeding or carcinomas, e.g., hepatocellular carcinoma (HCC) and intrahepatic cholangiocellular carcinoma (iCCCa), can occur. Intestinal fibrosis is one of the most devastating complications of Crohn's disease. With novel and consistent therapeutic interventions, fibrotic processes can be stopped and reversed. New research technologies have substantially improved our knowledge of liver fibrogenesis and intestinal fibrosis. The focus of this review article is on MASLD and Crohn's disease, chronic inflammatory diseases of the liver and intestines with increasing prevalence and a major impact on the general population. The current principles and potential possibilities of preventive and therapeutic antifibrotic interventions are illustrated.","PeriodicalId":73385,"journal":{"name":"Innere Medizin (Heidelberg, Germany)","volume":" ","pages":"695-701"},"PeriodicalIF":0.0,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143544756","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

[Pathophysiology of fibrosis: inflammatory vs. non-inflammatory]. [纤维化的病理生理学：炎性与非炎性]。

Innere Medizin (Heidelberg, Germany) Pub Date : 2025-07-01 Epub Date: 2025-04-03 DOI: 10.1007/s00108-025-01890-9

Elena Neumann, Philipp Klemm

引用次数: 0

[Efficacy of neuraminidase inhibitors against influenza]. 神经氨酸酶抑制剂抗流感的疗效

Innere Medizin (Heidelberg, Germany) Pub Date : 2025-07-01 Epub Date: 2025-06-06 DOI: 10.1007/s00108-025-01907-3

Theo Dähne, Sirka Nitschmann, Hartmut Hengel

引用次数: 0

[Blood vessels as a target organ: from Ormond's disease to immunoglobulin G4-related diseases]. 【血管作为靶器官：从奥蒙德病到免疫球蛋白g4相关疾病】。

Innere Medizin (Heidelberg, Germany) Pub Date : 2025-07-01 Epub Date: 2025-04-01 DOI: 10.1007/s00108-025-01891-8

Marco Krasselt, Bimba Hoyer

引用次数: 0

[Pharmacological inhibition of fibrosis exemplified by systemic sclerosis : Possibilities and limits]. [以系统性硬化症为例的纤维化的药理抑制：可能性和局限性]。

Innere Medizin (Heidelberg, Germany) Pub Date : 2025-07-01 Epub Date: 2025-06-27 DOI: 10.1007/s00108-025-01925-1

Tobias Dashi, Christina Bergmann

{"title":"[Pharmacological inhibition of fibrosis exemplified by systemic sclerosis : Possibilities and limits].","authors":"Tobias Dashi, Christina Bergmann","doi":"10.1007/s00108-025-01925-1","DOIUrl":"10.1007/s00108-025-01925-1","url":null,"abstract":"Fibrotic diseases, such as cardiac, liver and lung fibrosis are a heterogeneous group of diseases with high mortality and fatality rates. Identifying cross-disease mechanisms is a potential strategy to find targets for these sometimes rare diseases. Additionally, it is necessary to consider disease-specific differences. Systemic sclerosis (SSc) is an autoimmune, fibrotic systemic disease. The possibilities and limitations of the pharmacological inhibition of fibrosis are exemplified and discussed in this article using SSc as an example. The focus of the article is on relevant pathogenetic aspects, new insights into known therapeutic principles, emerging developments \"on the way to clinical application and ongoing studies\", as well as an outlook on open questions. Continuing innovations in the field of molecular biological and computer-assisted analytical methods are enabling an increasingly more precise understanding of fibrosing tissue processes, serving as a basis for identifying new treatment strategies and approaches. Numerous targeted therapies are currently in phase 2/phase 3 clinical trials and are expected to be concluded in the coming years. Additionally, innovative options for deep B‑cell depletion are available for clinical testing; however, a \"cure\" for fibrotic diseases has not yet been achieved, and further questions remain on the research agenda.","PeriodicalId":73385,"journal":{"name":"Innere Medizin (Heidelberg, Germany)","volume":" ","pages":"702-711"},"PeriodicalIF":0.0,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144509819","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0